Gilead Sciences, Inc.
—- Market cap
- $179.56B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $179.56B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: GILD stock price at discount vs VRTX $144.81 current versus $227.72 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRTX's multiple
Implied fair value · at GILD's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GILD can accelerate growth without materially increasing leverage, then GILD is the better relative-value pick because it trades at a much lower P/E and P/S than VRTX while still posting strong margins and a 7/9 Piotroski score.
GILD trades well below VRTX on both earnings and sales multiples, which implies substantial relative valuation discount. The gap is supported by GILD’s lower growth and lower quality-adjusted operating profile versus VRTX, but GILD’s absolute price also sits near the upper half of its historical band.
Supporting Metrics